Black Diamond Therapeutics(BDTX) - 2025 Q1 - Quarterly Results

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update CAMBRIDGE, MA, May 12, 2025 (GLOBE NEWSWIRE) – Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. • In the fourth quarter of 2025, Black Diamond expects to disclose ini ...